Asset Details
Do you wish to reserve the book?
Expression of mTOR in normal and pathological conditions
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Expression of mTOR in normal and pathological conditions
Do you wish to request the book?
Expression of mTOR in normal and pathological conditions
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Expression of mTOR in normal and pathological conditions
2023
Overview
The mechanistic/mammalian target of rapamycin (mTOR), a protein discovered in 1991, integrates a complex pathway with a key role in maintaining cellular homeostasis. By comprising two functionally distinct complexes, mTOR complex 1 (mTORC1) and mTORC2, it is a central cellular hub that integrates intra- and extracellular signals of energy, nutrient, and hormone availability, modulating the molecular responses to acquire a homeostatic state through the regulation of anabolic and catabolic processes. Accordingly, dysregulation of mTOR pathway has been implicated in a variety of human diseases. While major advances have been made regarding the regulators and effectors of mTOR signaling pathway, insights into the regulation of mTOR gene expression are beginning to emerge. Here, we present the current available data regarding the mTOR expression regulation at the level of transcription, translation and mRNA stability and systematize the current knowledge about the fluctuations of mTOR expression observed in several diseases, both cancerous and non-cancerous. In addition, we discuss whether mTOR expression changes can be used as a biomarker for diagnosis, disease progression, prognosis and/or response to therapeutics. We believe that our study will contribute for the implementation of new disease biomarkers based on mTOR as it gives an exhaustive perspective about the regulation of mTOR gene expression in both normal and pathological conditions.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Biomedical and Life Sciences
/ Cancer
/ Diabetes
/ Humans
/ Insulin
/ Kinases
/ Mechanistic Target of Rapamycin Complex 1 - genetics
/ Mechanistic Target of Rapamycin Complex 1 - metabolism
/ Mechanistic Target of Rapamycin Complex 2 - genetics
/ Mechanistic Target of Rapamycin Complex 2 - metabolism
/ mTOR transcriptional regulation
/ Multiprotein Complexes - metabolism
/ Oncology
/ Proteins
/ Review
/ TOR Serine-Threonine Kinases - genetics
/ TOR Serine-Threonine Kinases - metabolism
/ Yeast
